Approval · Notice of Compliance 14787 · 2013
NTP-SUMATRIPTAN DF: Notice of Compliance 14787
Issued October 4, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14787
- Date
- October 4, 2013
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Merger/buyout
- Therapeutic class
- 5-ht1 receptor agonist, migraine therapy
- Canadian reference product
- IMITREX DF
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NTP-SUMATRIPTAN DF | 02358719 | Cancelled Pre Market |
| NTP-SUMATRIPTAN DF | 02358727 | Cancelled Pre Market |
| NTP-SUMATRIPTAN DF | 02358735 | Cancelled Pre Market |
Medicinal ingredients
- SUMATRIPTAN SUCCINATE 25 MG per TAB
- SUMATRIPTAN SUCCINATE 50 MG per TAB
- SUMATRIPTAN SUCCINATE 100 MG per TAB